EHMT1 and neurodevelopmental disorder: Our previous work investigating reduced dosage of TCF4 and EHMT1 suggested that modeling genomic dosage disorders in NSCs made them more characteristic of a differentiating cell state compared with their actual proliferating state, implying a convergence point for at least some neurodevelopmental disorders.33 To test this hypothesis in the MBD5 KD and SATB2 KD models, we performed RNAseq using two shRNA constructs per gene and four non-target control shRNA, then generated a list of differentially expressed genes for each reduced dosage model compared with control shRNA.